Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

10    Johnson & Johnson    $12.1B     down 6.2%
Global revenue: $65.0B (2nd); up 5.5%

R&D spend: $7.5B (5th), up 10.3%; 11.5% of rev.

Top brands: Remicade ($3.5B), Procrit ($1.2B), Concerta ($856M), Levaquin ($778), Prezista ($630M)

Planned launches: Canagliflozin (diab.), TMC-435 (HCV), bapineuzumab (Alz.)

Promotional spend: $438M (13th); 3.6% of rev.

Patent expirations: Remicade (2014), Prezista (2016), Zytiga (2016)

J&J's past year can be summed up in one word: recalls. The healthcare products giant had a lot of them, fueling discussions of a company that has lost its luster. This came in addition to lawsuits alleging fraudulent marketing of its antipsychotic Risperdal. The impact of these missteps shows: the government shutdown of a McNeil plant hurt inventory levels, and OTC sales fell 3% in the US last year. But a recent poll showed consumers are still attached to J&J. CEO William Weldon, who was in place during much of the product recalls, was replaced by Alex Gorsky.

Back to first page

Page 10 of 21
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"